Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia 2Recurrence 1Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Burkitt Lymphoma 1

Interventions

pembrolizumab 9trastuzumab deruxtecan 5trametinib 4dabrafenib 4zanubrutinib 3nilotinib 3fludarabine 3Trastuzumab 3Dexamethasone 3Cyclophosphamide 3tucatinib 2tisagenlecleucel 2selinexor 2relatlimab 2pemigatinib 2larotrectinib 2ipatasertib 2erdafitinib 2entrectinib 2enfortumab vedotin 2defactinib 2daratumumab 2blinatumomab 2binimetinib 2belzutifan 2axicabtagene ciloleucel 2atezolizumab 2TIC10 compound 2Sunitinib 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Has announcements × blinatumomab × Clear all
NCT02000427 2024-05-28

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Amgen

Phase 2 Completed
45 enrolled 24 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01207388 2020-02-10

BLAST

Amgen Research (Munich) GmbH

Phase 2 Completed
116 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡